Spyglass Pharma, Inc.’s (NASDAQ:SGP) Quiet Period Will Expire on March 18th

Spyglass Pharma’s (NASDAQ:SGP) quiet period is set to end on Wednesday, March 18th. Spyglass Pharma had issued 9,375,000 shares in its public offering on February 6th. The total size of the offering was $150,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

SGP has been the subject of several research analyst reports. Citigroup started coverage on Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 price objective for the company. Leerink Partners cut shares of Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Zacks Research raised shares of Spyglass Pharma to a “hold” rating in a report on Wednesday, March 4th. Wall Street Zen upgraded shares of Spyglass Pharma to a “hold” rating in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus initiated coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They set a “buy” rating and a $42.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Spyglass Pharma currently has an average rating of “Moderate Buy” and an average target price of $45.00.

Spyglass Pharma Trading Down 2.5%

Shares of NASDAQ:SGP opened at $26.42 on Friday. Spyglass Pharma has a twelve month low of $20.16 and a twelve month high of $32.44.

Insider Buying and Selling

In other Spyglass Pharma news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the completion of the transaction, the director owned 5,966,439 shares of the company’s stock, valued at approximately $95,463,024. The trade was a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Key Stories Impacting Spyglass Pharma

Here are the key news stories impacting Spyglass Pharma this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $37 price target, which can attract new institutional interest and provide a valuation anchor for the stock. Spyglass Pharma (NASDAQ:SGP) Coverage Initiated at HC Wainwright
• Positive Sentiment: Spyglass announced positive 12‑month topline results from its Phase 1/2 trial of the BIM‑IOL system — a clinical milestone that de‑risks the program and supports future commercialization/value capture if subsequent data and regulatory paths remain favorable. SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
• Positive Sentiment: A separate report cites analysts setting a $47 price target on SGP, signaling that some coverage models view substantially higher upside than current levels. That can support speculative buying and re-rate potential. Analysts Set Spyglass Pharma, Inc. (NASDAQ:SGP) Price Target at $47.00
• Neutral Sentiment: HC Wainwright published detailed EPS forecasts across multiple quarters and years while maintaining the Buy rating; the update provides a clearer earnings trajectory for modelers but is a reiteration of analyst coverage rather than new corporate guidance. MarketBeat SGP coverage summary
• Negative Sentiment: HC Wainwright’s EPS projections show large near‑term losses (e.g., FY2025 forecast of roughly ($19.06) and continued quarterly losses in 2026), highlighting significant expected cash burn/dilution risk. Those sizable loss estimates can weigh on the stock despite positive clinical news and Buy ratings — and likely help explain downward pressure today. MarketBeat SGP coverage summary

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).